PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
-0.71 (-1.65%)
At close: 4:01PM EST

42.68 +0.28 (0.66%)
After hours: 6:47PM EST

Stock chart is not supported by your current browser
Previous Close43.11
Bid0.00 x 800
Ask42.68 x 1000
Day's Range42.04 - 43.50
52 Week Range33.20 - 46.47
Avg. Volume23,332,685
Market Cap245.092B
Beta (3Y Monthly)0.75
PE Ratio (TTM)10.71
EPS (TTM)3.96
Earnings DateJan 28, 2019 - Feb 1, 2019
Forward Dividend & Yield1.44 (3.29%)
Ex-Dividend Date2018-11-08
1y Target Est44.78
Trade prices are not sourced from all markets
  • Boeing Is Still among Dow’s Best Performers despite the Sell-Off
    Market Realist5 hours ago

    Boeing Is Still among Dow’s Best Performers despite the Sell-Off

    Over the past month, shares of the Boeing Company (BA) have been battered significantly as a result of multiple headwinds. Boeing holds the eighth-place spot among the 16 Dow 30 stocks that have posted YTD gains. Boeing was the Dow’s top performer for most of 2017, earning its investors 88% in the year.

  • Pfizer: Recent Developments and Analysts’ Recommendations
    Market Realist11 hours ago

    Pfizer: Recent Developments and Analysts’ Recommendations

    On December 14, Pfizer (PFE) announced a dividend of $0.36 for the first quarter of fiscal 2019. Pfizer announced that the dividend would be payable to shareholders on record at the close of the market on February 1. Pfizer’s dividend of $0.36 is 6% higher than the previous dividend of $0.34.

  • Business Wire12 hours ago

    Pfizer Invites Public to View and Listen to Webcast of January 29 Conference Call with Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 29, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at

  • Benzinga13 hours ago

    Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved

    Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...

  • 3 Reasons Why Pfizer's Latest Dividend Hike Is Better Than You Might Think
    Motley Fool16 hours ago

    3 Reasons Why Pfizer's Latest Dividend Hike Is Better Than You Might Think

    Pfizer's 6% dividend increase is good news. But here's what makes it even better.

  • Pfizer (PFE) Stock Moves -1.58%: What You Should Know

    Pfizer (PFE) Stock Moves -1.58%: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $43.11, marking a -1.58% move from the previous day.

  • Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod

    Pfizer's (PFE) Biosimilar of Avastin Gets Positive CHMP Nod

    Pfizer (PFE) gets positive CHMP opinion for Zirabev (bevacizumab), a potential biosimilar to Roche's Avastin (bevacizumab).

  • Zacks2 days ago

    Lilly (LLY) to Acquire Pain Candidate From Private Biotech

    Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.

  • PR Newswire2 days ago

    Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

    Kineta Immuno-Oncology to receive $15 million upfront and will be eligible to receive up to $505 million in potential research, development and sales milestone payments Research collaboration focused on ...

  • Stock Market Power Rankings: Down Is the New Up
    Motley Fool3 days ago

    Stock Market Power Rankings: Down Is the New Up

    They're big, beautiful, and ranked from 1 to 50.

  • Do Analysts See Any Upside for Ionis Stock?
    Market Realist4 days ago

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds,” and two have given it “sells.”

  • Understanding Ionis Pharmaceuticals’ Operational Performance
    Market Realist4 days ago

    Understanding Ionis Pharmaceuticals’ Operational Performance

    In the most recent quarter, Ionis Pharmaceuticals’ (IONS) selling, general, and administrative expenses rose YoY (year-over-year) to $68.71 million from $26.79 million. Meanwhile, its R&D (research and development) expenses rose YoY to $95.25 million from $80.21 million due to higher drug development costs.

  • Taking Stock of Ionis’s Performance
    Market Realist4 days ago

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.

  • TheStreet.com4 days ago

    Pfizer Boosts Q1 Dividend, Launches $10 Billion Buyback as Read Says Farewell

    shares traded lower Friday even as the pharmaceutical group boosted it latest quarterly dividend and said it would buyback another $10 million in company stock in what may be the last corporate act of outgoing CEO Ian Read. Pfizer said it had approved a 36 cents per share dividend, a 6% increase from the same period last year which will be paid on March 1 and authorized a new, $10 billion share repurchase plan, adding to an existing program of around $4.9 billion, which will be phased in over an unspecified period of time. The first quarter dividend is Pfizer's 321st consecutive shareholder payout by the New York based pharmaceutical group.

  • Reuters4 days ago

    Pfizer's cut-price version of Avastin wins EU panel greenlight

    A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin. Pfizer's Zirabev is the second cancer biosimilar from the drugmaker to receive a positive opinion from the European advisory panel this year. Roche has been facing declining sales for its three leading cancer drugs - Avastin, Herceptin, Rituxan - due to severe competition from low-cost versions called biosimilars.

  • Business Wire4 days ago

    Pfizer Declares First-Quarter 2019 Dividend

    The board of directors of Pfizer Inc. today declared a 36-cent first-quarter 2019 dividend on the company’s common stock, payable March 1, 2019, to shareholders of record at the close of business on February 1, 2019. Pfizer increased the dividend by approximately 6 percent, to 36 cents from 34 cents per share. The first-quarter 2019 cash dividend will be the 321st consecutive quarterly dividend paid by Pfizer.

  • Business Wire4 days ago

    Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)

    ZIRABEV™ , a potential biosimilar to Avastin®* , is Pfizer’s second therapeutic oncology biosimilar to receive a positive CHMP opinion in Europe in 2018

  • Zacks5 days ago

    Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus

    AstraZeneca's (AZN) Imfinzi misses endpoint in study. Roche's (RHHBY) cancer drug combo gets FDA nod for first-line lung cancer. Lilly (LLY) & Bristol Myers (BMY) sign new deals.

  • Reuters5 days ago

    Merck bolsters animal health unit with $2.4 bln Antelliq purchase

    Merck and Co said on Friday it will buy privately held French company Antelliq Group, which makes digital identification products for livestock, for about 2.1 billion euros ($2.37 billion) to bolster its fast-growing animal health business. The move affirms the drugmaker's commitment to the business, which Wall Street analysts have long seen value in separating just as rival drugmakers Eli Lilly and Co and Pfizer Inc did. Pfizer's Zoetis raised $2.2 billion in a 2013 IPO, while Elanco, the former animal health business at Lilly, raised $1.51 billion from an IPO in September.

  • Business Wire5 days ago

    Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

    Pfizer Inc. (PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. “While the full extent of Prevenar 13 protection of adults is still being realized, we anticipate our 20vPnC vaccine candidate will be the next important step to help protect adults from a substantial invasive pneumococcal disease and pneumonia burden, including disease caused by serotypes not yet covered by any available conjugate vaccine,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer.

  • ACCESSWIRE5 days ago

    Today's Research Reports on Trending Tickers: Pfizer and Merck & Co.

    NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...

  • A Closer Look at Biogen’s Gross Margin Trends
    Market Realist5 days ago

    A Closer Look at Biogen’s Gross Margin Trends

    In 2018 and 2019, Biogen (BIIB) is expected to generate revenues of $13.31 billion and $13.66 billion, respectively, compared to $12.27 billion in 2017.